Department of Medicine, University of Washington, VA Puget Sound Health Care System, Seattle, WA 98108, USA.
Trends Immunol. 2012 Nov;33(11):546-53. doi: 10.1016/j.it.2012.07.002. Epub 2012 Aug 14.
Recent advances in understanding the etiology of obesity, metabolic syndrome, and type 2 diabetes (T2D) have established involvement of the immune system. These developments highlight the potential of immunomodulatory therapies for treatment of these conditions. Here, we discuss current and new immunotherapeutic strategies for the treatment of T2D, the need for stratification of patients based on immune and autoimmune status, and biomarkers for evaluating treatment efficiency. The time has come to re-evaluate the clinical management of T2D patients using metabolic parameters alone, and to realize that patients should be stratified based on their immune and/or autoimmune status prior to initiation of therapy to realize fully the potential of immunomodulatory strategies for T2D.
近年来，人们对肥胖症、代谢综合征和 2 型糖尿病（T2D）病因的认识不断深入，已经确定免疫系统参与其中。这些进展凸显了免疫调节疗法治疗这些疾病的潜力。在这里，我们讨论了用于治疗 T2D 的当前和新的免疫治疗策略、根据免疫和自身免疫状态对患者进行分层的必要性，以及评估治疗效果的生物标志物。现在是时候重新评估仅使用代谢参数来管理 T2D 患者，并且应该认识到，在开始治疗之前，应根据患者的免疫和/或自身免疫状态对其进行分层，以充分发挥免疫调节策略治疗 T2D 的潜力。
